Private Ocean LLC Boosts Stock Holdings in Edwards Lifesciences Corp (NYSE:EW)

Private Ocean LLC boosted its position in Edwards Lifesciences Corp (NYSE:EW) by 43.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 575 shares of the medical research company’s stock after purchasing an additional 175 shares during the period. Private Ocean LLC’s holdings in Edwards Lifesciences were worth $127,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of EW. Bath Savings Trust Co lifted its position in shares of Edwards Lifesciences by 7.7% during the second quarter. Bath Savings Trust Co now owns 27,121 shares of the medical research company’s stock worth $5,010,000 after acquiring an additional 1,949 shares in the last quarter. WINTON GROUP Ltd increased its holdings in shares of Edwards Lifesciences by 41.1% in the second quarter. WINTON GROUP Ltd now owns 5,744 shares of the medical research company’s stock worth $1,061,000 after purchasing an additional 1,673 shares during the period. RDA Financial Network increased its holdings in shares of Edwards Lifesciences by 6.9% in the second quarter. RDA Financial Network now owns 4,313 shares of the medical research company’s stock worth $805,000 after purchasing an additional 280 shares during the period. New England Research & Management Inc. bought a new position in shares of Edwards Lifesciences in the second quarter worth $323,000. Finally, Harbour Capital Advisors LLC increased its holdings in shares of Edwards Lifesciences by 0.9% in the second quarter. Harbour Capital Advisors LLC now owns 11,085 shares of the medical research company’s stock worth $2,048,000 after purchasing an additional 98 shares during the period. Institutional investors and hedge funds own 81.31% of the company’s stock.

In other news, CEO Michael A. Mussallem sold 22,850 shares of the firm’s stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $238.79, for a total transaction of $5,456,351.50. Following the transaction, the chief executive officer now directly owns 95,770 shares of the company’s stock, valued at $22,868,918.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Larry L. Wood sold 6,716 shares of the firm’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $239.75, for a total value of $1,610,161.00. Following the transaction, the vice president now directly owns 124,145 shares in the company, valued at $29,763,763.75. The disclosure for this sale can be found here. In the last three months, insiders sold 146,103 shares of company stock worth $32,806,079. 1.63% of the stock is owned by insiders.

Several research firms have recently weighed in on EW. BMO Capital Markets upped their price target on shares of Edwards Lifesciences from $204.00 to $224.00 and gave the stock an “outperform” rating in a report on Wednesday, July 24th. Morgan Stanley upped their price target on shares of Edwards Lifesciences from $228.00 to $248.00 and gave the stock an “overweight” rating in a report on Thursday, October 24th. Stifel Nicolaus upped their price target on shares of Edwards Lifesciences from $215.00 to $250.00 and gave the stock a “buy” rating in a report on Thursday, October 24th. Raymond James upped their price target on shares of Edwards Lifesciences from $250.00 to $255.00 and gave the stock an “outperform” rating in a report on Thursday, October 24th. Finally, Barclays upped their price target on shares of Edwards Lifesciences from $160.00 to $175.00 and gave the stock an “underweight” rating in a report on Wednesday, July 24th. Two analysts have rated the stock with a sell rating, five have given a hold rating and thirteen have issued a buy rating to the company’s stock. Edwards Lifesciences currently has a consensus rating of “Buy” and a consensus target price of $237.89.

EW traded down $0.99 during trading on Friday, reaching $234.16. The stock had a trading volume of 813,724 shares, compared to its average volume of 1,239,245. The stock has a market cap of $48.47 billion, a PE ratio of 49.82, a PEG ratio of 2.81 and a beta of 0.82. The company has a debt-to-equity ratio of 0.17, a quick ratio of 2.74 and a current ratio of 3.53. Edwards Lifesciences Corp has a one year low of $139.64 and a one year high of $241.82. The business has a 50-day moving average of $226.79 and a 200-day moving average of $203.32.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Wednesday, October 23rd. The medical research company reported $1.41 EPS for the quarter, beating the Zacks’ consensus estimate of $1.22 by $0.19. The business had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.04 billion. Edwards Lifesciences had a return on equity of 32.28% and a net margin of 18.64%. The firm’s revenue was up 20.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.07 earnings per share. Equities research analysts forecast that Edwards Lifesciences Corp will post 5.6 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Further Reading: Diversification Important in Investing

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.